A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Latest Information Update: 10 Apr 2024
Price :
$35 *
At a glance
- Drugs Sovateltide (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Pharmazz
- 04 Apr 2024 Status changed from not yet recruiting to recruiting.
- 25 Sep 2023 Planned initiation date changed from 1 Sep 2023 to 1 Nov 2023.
- 25 Sep 2023 Status changed from recruiting to not yet recruiting.